Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of beperminogene perplasmid (AMG0001) in Fontaine grade III PAD
jRCT1080224997Phase 3Completed
- Sponsor
- AnGes, Inc.
- Start
- Dec 2019
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in arteriosclerosis obliterans comparing Beperminogene perplasmid with Placebo (2 arms). Started Dec 2019; status: completed.
02
Drugs
beperminogene perplasmid
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT1080224997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224997.